{"transactions":[{"id":4634315,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10585,"kind":"person","name":"Quaggin Susan E","position":1,"cik":"0001997505","reported_name":"Quaggin Susan E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Equivalent Units","published_at":"2026-10-03T01:00:11.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":59,"price":261.59,"value":15433.81,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature."}],"balance_after":918,"derivative":{"exercise_price":261.59,"underlying":"Common Stock","underlying_shares":59},"source":{"system":"sec-edgar","filing":"0001997505-26-000010","document":"form4-10022026_051005.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1997505/000199750526000010/form4-10022026_051005.xml","form_type":"4"}},{"id":4634026,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10596,"kind":"person","name":"RAPP EDWARD J","position":1,"cik":"0001171780","reported_name":"RAPP EDWARD J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Equivalent Units","published_at":"2026-10-03T01:00:07.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":129,"price":261.59,"value":33745.11,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature."}],"balance_after":29568,"derivative":{"exercise_price":261.59,"underlying":"Common Stock","underlying_shares":129},"source":{"system":"sec-edgar","filing":"0001171780-26-000014","document":"form4-10022026_051002.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1171780/000117178026000014/form4-10022026_051002.xml","form_type":"4"}},{"id":5610,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Option (Right to buy)","published_at":"2026-08-18T21:00:16.000Z","date":"2026-08-14","kind":"exercise","planned":false,"acquired":false,"shares":32710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022."}],"balance_after":0,"derivative":{"exercise_price":79.02,"expiration_date":"2029-02-20","underlying":"Common Stock","underlying_shares":32710},"source":{"system":"sec-edgar","filing":"0001762951-26-000006","document":"form4-08182026_050811.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000006/form4-08182026_050811.xml","form_type":"4"}},{"id":5609,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-08-18T21:00:16.000Z","date":"2026-08-14","kind":"sale","planned":false,"acquired":false,"shares":32710,"price":250,"value":8177500.0,"ownership":{"direct":true},"balance_after":74430,"source":{"system":"sec-edgar","filing":"0001762951-26-000006","document":"form4-08182026_050811.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000006/form4-08182026_050811.xml","form_type":"4"}},{"id":5608,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-08-18T21:00:16.000Z","date":"2026-08-14","kind":"exercise","planned":false,"acquired":true,"shares":32710,"price":79.02,"value":2584744.2,"ownership":{"direct":true},"balance_after":107140,"source":{"system":"sec-edgar","filing":"0001762951-26-000006","document":"form4-08182026_050811.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000006/form4-08182026_050811.xml","form_type":"4"}},{"id":7084,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10596,"kind":"person","name":"RAPP EDWARD J","position":1,"cik":"0001171780","reported_name":"RAPP EDWARD J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Equivalent Units","published_at":"2026-07-02T21:00:14.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":134,"price":251.64,"value":33719.76,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature."}],"balance_after":29236,"derivative":{"exercise_price":251.64,"underlying":"Common Stock","underlying_shares":134},"source":{"system":"sec-edgar","filing":"0001171780-26-000012","document":"form4-07022026_050703.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1171780/000117178026000012/form4-07022026_050703.xml","form_type":"4"}},{"id":7055,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10585,"kind":"person","name":"Quaggin Susan E","position":1,"cik":"0001997505","reported_name":"Quaggin Susan E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Equivalent Units","published_at":"2026-07-02T21:00:12.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":62,"price":251.64,"value":15601.68,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Director fees credited to an unfunded book account in the director's name are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature."}],"balance_after":853,"derivative":{"exercise_price":251.64,"underlying":"Common Stock","underlying_shares":62},"source":{"system":"sec-edgar","filing":"0001997505-26-000008","document":"form4-07022026_050702.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1997505/000199750526000008/form4-07022026_050702.xml","form_type":"4"}},{"id":9914,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10826,"kind":"person","name":"FALK THOMAS J","position":1,"cik":"0001222890","reported_name":"FALK THOMAS J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value","published_at":"2026-05-12T21:00:31.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":1118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the \"Program\"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program)."}],"balance_after":2321,"source":{"system":"sec-edgar","filing":"0001222890-26-000003","document":"form4-05122026_050524.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222890/000122289026000003/form4-05122026_050524.xml","form_type":"4"}},{"id":9913,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10825,"kind":"person","name":"WADDELL FREDERICK H","position":1,"cik":"0001223690","reported_name":"WADDELL FREDERICK H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value","published_at":"2026-05-12T21:00:28.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":1118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the \"Program\"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program)."}],"balance_after":30076,"source":{"system":"sec-edgar","filing":"0001223690-26-000004","document":"form4-05122026_050522.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1223690/000122369026000004/form4-05122026_050522.xml","form_type":"4"}},{"id":9911,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10823,"kind":"person","name":"Roberts Rebecca B","position":1,"cik":"0001355580","reported_name":"Roberts Rebecca B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value","published_at":"2026-05-12T21:00:26.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":1118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the \"Program\"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program)."}],"balance_after":14846,"source":{"system":"sec-edgar","filing":"0001355580-26-000002","document":"form4-05122026_050520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1355580/000135558026000002/form4-05122026_050520.xml","form_type":"4"}},{"id":9918,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10596,"kind":"person","name":"RAPP EDWARD J","position":1,"cik":"0001171780","reported_name":"RAPP EDWARD J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value","published_at":"2026-05-12T21:00:25.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":1118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the \"Program\"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 10,388 shares in trust previously held indirectly by spouse, now held directly."}],"balance_after":45964,"source":{"system":"sec-edgar","filing":"0001171780-26-000010","document":"form4-05122026_050518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1171780/000117178026000010/form4-05122026_050518.xml","form_type":"4"}},{"id":9906,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10585,"kind":"person","name":"Quaggin Susan E","position":1,"cik":"0001997505","reported_name":"Quaggin Susan E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value","published_at":"2026-05-12T21:00:23.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":1118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the \"Program\"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program)."}],"balance_after":3643,"source":{"system":"sec-edgar","filing":"0001997505-26-000006","document":"form4-05122026_050515.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1997505/000199750526000006/form4-05122026_050515.xml","form_type":"4"}},{"id":9908,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10820,"kind":"person","name":"MEYER MELODY B","position":1,"cik":"0001706126","reported_name":"MEYER MELODY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value","published_at":"2026-05-12T21:00:18.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":1118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the \"Program\"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program)."}],"balance_after":17616,"source":{"system":"sec-edgar","filing":"0001706126-26-000002","document":"form4-05122026_050513.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000170612626000002/form4-05122026_050513.xml","form_type":"4"}},{"id":9910,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10822,"kind":"person","name":"Hart Brett J","position":1,"cik":"0001466338","reported_name":"Hart Brett J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value","published_at":"2026-05-12T21:00:15.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":1118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the \"Program\"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program)."}],"balance_after":20590,"source":{"system":"sec-edgar","filing":"0001466338-26-000003","document":"form4-05122026_050511.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1466338/000146633826000003/form4-05122026_050511.xml","form_type":"4"}},{"id":9912,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10824,"kind":"person","name":"FREYMAN THOMAS C","position":1,"cik":"0001239126","reported_name":"FREYMAN THOMAS C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value","published_at":"2026-05-12T21:00:13.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":1118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the \"Program\"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program)."}],"balance_after":127869,"source":{"system":"sec-edgar","filing":"0001239126-26-000002","document":"form4-05122026_050509.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239126/000123912626000002/form4-05122026_050509.xml","form_type":"4"}},{"id":9907,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10819,"kind":"person","name":"Davis Jennifer L.","position":1,"cik":"0001916665","reported_name":"Davis Jennifer L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value","published_at":"2026-05-12T21:00:12.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":1118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the \"Program\"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program)."}],"balance_after":3643,"source":{"system":"sec-edgar","filing":"0001916665-26-000002","document":"form4-05122026_050507.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000191666526000002/form4-05122026_050507.xml","form_type":"4"}},{"id":9909,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10821,"kind":"person","name":"BURNSIDE WILLIAM H.L.","position":1,"cik":"0001563579","reported_name":"BURNSIDE WILLIAM H.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value","published_at":"2026-05-12T21:00:09.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":1118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the \"Program\"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program)."}],"balance_after":28076,"source":{"system":"sec-edgar","filing":"0001563579-26-000002","document":"form4-05122026_050505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000156357926000002/form4-05122026_050505.xml","form_type":"4"}},{"id":9929,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10830,"kind":"person","name":"AUSTIN ROXANNE S","position":1,"cik":"0001061632","reported_name":"AUSTIN ROXANNE S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value","published_at":"2026-05-12T21:00:07.000Z","date":"2026-05-08","kind":"grant","planned":false,"acquired":true,"shares":1118,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the \"Program\"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program)."}],"balance_after":39576,"source":{"system":"sec-edgar","filing":"0001061632-26-000004","document":"form4-05122026_050501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061632/000106163226000004/form4-05122026_050501.xml","form_type":"4"}},{"id":10988,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10585,"kind":"person","name":"Quaggin Susan E","position":1,"cik":"0001997505","reported_name":"Quaggin Susan E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Equivalent Units","published_at":"2026-04-02T21:00:15.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":71,"price":217.49,"value":15441.79,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature."}],"balance_after":784,"derivative":{"exercise_price":217.49,"underlying":"Common Stock","underlying_shares":71},"source":{"system":"sec-edgar","filing":"0001997505-26-000004","document":"form4-04022026_050411.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1997505/000199750526000004/form4-04022026_050411.xml","form_type":"4"}},{"id":11003,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10596,"kind":"person","name":"RAPP EDWARD J","position":1,"cik":"0001171780","reported_name":"RAPP EDWARD J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Equivalent Units","published_at":"2026-04-02T21:00:14.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":155,"price":217.49,"value":33710.95,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature."}],"balance_after":28865,"derivative":{"exercise_price":217.49,"underlying":"Common Stock","underlying_shares":155},"source":{"system":"sec-edgar","filing":"0001171780-26-000006","document":"form4-04022026_050408.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1171780/000117178026000006/form4-04022026_050408.xml","form_type":"4"}},{"id":10999,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10966,"kind":"person","name":"Alpern Robert J","position":1,"cik":"0001448074","reported_name":"Alpern Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Equivalent Units","published_at":"2026-04-02T21:00:11.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":35,"price":217.49,"value":7612.15,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature."}],"balance_after":10369,"derivative":{"exercise_price":217.49,"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001448074-26-000007","document":"form4-04022026_050406.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448074/000144807426000007/form4-04022026_050406.xml","form_type":"4"}},{"id":11895,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10993,"kind":"person","name":"Purdue David Ryan","position":1,"cik":"0002057696","reported_name":"Purdue David Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-11T17:00:20.000Z","date":"2026-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":2108,"price":232.08,"value":489224.64,"ownership":{"direct":true},"balance_after":8468,"source":{"system":"sec-edgar","filing":"0002057696-26-000010","document":"form4a-03112026_050317.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2057696/000205769626000010/form4a-03112026_050317.xml","form_type":"4/A","original_submission_date":"2026-03-03"}},{"id":11987,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11009,"kind":"person","name":"Crum Demetris D","position":1,"cik":"0002078592","reported_name":"Crum Demetris D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF HR OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-06T22:02:27.000Z","date":"2026-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":1594,"price":232.08,"value":369935.52,"ownership":{"direct":true},"balance_after":7914,"source":{"system":"sec-edgar","filing":"0002078592-26-000004","document":"form4-03062026_100324.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000207859226000004/form4-03062026_100324.xml","form_type":"4"}},{"id":11988,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10993,"kind":"person","name":"Purdue David Ryan","position":1,"cik":"0002057696","reported_name":"Purdue David Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-06T17:05:44.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":5230,"price":233.56,"value":1221518.8,"ownership":{"direct":true},"balance_after":2654,"source":{"system":"sec-edgar","filing":"0002057696-26-000008","document":"form4-03062026_100340.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2057696/000205769626000008/form4-03062026_100340.xml","form_type":"4"}},{"id":12328,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-03T23:14:39.000Z","date":"2026-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":8037,"price":232.08,"value":1865226.96,"ownership":{"direct":true},"balance_after":52376,"source":{"system":"sec-edgar","filing":"0002004979-26-000004","document":"form4-03032026_110334.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000200497926000004/form4-03032026_110334.xml","form_type":"4"}},{"id":12465,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11034,"kind":"person","name":"Stewart Jeffrey Ryan","position":1,"cik":"0001761675","reported_name":"Stewart Jeffrey Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-03T23:10:14.000Z","date":"2026-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":23812,"price":232.08,"value":5526288.96,"ownership":{"direct":true},"balance_after":83171,"source":{"system":"sec-edgar","filing":"0001761675-26-000004","document":"form4-03032026_060311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000176167526000004/form4-03032026_060311.xml","form_type":"4"}},{"id":12431,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11031,"kind":"person","name":"Siatis Perry C","position":1,"cik":"0001951400","reported_name":"Siatis Perry C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC AND SECRETARY"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-03T23:10:12.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":2600,"price":235.26,"value":611676.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.14 to $235.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4619,"source":{"system":"sec-edgar","filing":"0001951400-26-000006","document":"form4-03032026_060309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000195140026000006/form4-03032026_060309.xml","form_type":"4"}},{"id":12430,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11031,"kind":"person","name":"Siatis Perry C","position":1,"cik":"0001951400","reported_name":"Siatis Perry C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC AND SECRETARY"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-03T23:10:12.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":10291,"price":234.66,"value":2414886.06,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.14 to $235.12, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":7219,"source":{"system":"sec-edgar","filing":"0001951400-26-000006","document":"form4-03032026_060309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000195140026000006/form4-03032026_060309.xml","form_type":"4"}},{"id":12429,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11031,"kind":"person","name":"Siatis Perry C","position":1,"cik":"0001951400","reported_name":"Siatis Perry C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC AND SECRETARY"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-03T23:10:12.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":5777,"price":233.51,"value":1348987.27,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $233 to $233.99, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":17510,"source":{"system":"sec-edgar","filing":"0001951400-26-000006","document":"form4-03032026_060309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000195140026000006/form4-03032026_060309.xml","form_type":"4"}},{"id":12428,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11031,"kind":"person","name":"Siatis Perry C","position":1,"cik":"0001951400","reported_name":"Siatis Perry C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC AND SECRETARY"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-03T23:10:12.000Z","date":"2026-02-27","kind":"tax_withholding","planned":true,"acquired":false,"shares":14850,"price":232.08,"value":3446388.0,"ownership":{"direct":true},"balance_after":23287,"source":{"system":"sec-edgar","filing":"0001951400-26-000006","document":"form4-03032026_060309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000195140026000006/form4-03032026_060309.xml","form_type":"4"}},{"id":12432,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11032,"kind":"person","name":"Reents Scott T","position":1,"cik":"0001937048","reported_name":"Reents Scott T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-03T23:10:11.000Z","date":"2026-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":21638,"price":232.08,"value":5021747.04,"ownership":{"direct":true},"balance_after":38777,"source":{"system":"sec-edgar","filing":"0001937048-26-000004","document":"form4-03032026_060305.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000193704826000004/form4-03032026_060305.xml","form_type":"4"}},{"id":12491,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-03T23:10:10.000Z","date":"2026-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":16309,"price":232.08,"value":3784992.72,"ownership":{"direct":true},"balance_after":197794,"source":{"system":"sec-edgar","filing":"0001563545-26-000004","document":"form4-03032026_060307.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000156354526000004/form4-03032026_060307.xml","form_type":"4"}},{"id":12464,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-03T23:10:06.000Z","date":"2026-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":12874,"price":232.08,"value":2987797.92,"ownership":{"direct":true},"balance_after":74430,"source":{"system":"sec-edgar","filing":"0001762951-26-000004","document":"form4-03032026_060301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000004/form4-03032026_060301.xml","form_type":"4"}},{"id":12474,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHAIRMAN OF THE BOARD AND CEO"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-03T18:12:11.000Z","date":"2026-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":36523,"price":232.08,"value":8476257.84,"ownership":{"direct":true},"balance_after":178737,"source":{"system":"sec-edgar","filing":"0001699914-26-000004","document":"form4-03032026_110308.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000169991426000004/form4-03032026_110308.xml","form_type":"4"}},{"id":12308,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10993,"kind":"person","name":"Purdue David Ryan","position":1,"cik":"0002057696","reported_name":"Purdue David Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-03T18:10:10.000Z","date":"2026-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":2692,"price":232.08,"value":624759.36,"ownership":{"direct":true},"balance_after":7884,"source":{"system":"sec-edgar","filing":"0002057696-26-000004","document":"form4-03032026_060303.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2057696/000205769626000004/form4-03032026_060303.xml","form_type":"4"}},{"id":12778,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11031,"kind":"person","name":"Siatis Perry C","position":1,"cik":"0001951400","reported_name":"Siatis Perry C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC AND SECRETARY"}}],"security":"Option (Right to buy)","published_at":"2026-02-27T22:00:05.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":false,"shares":7292,"price":192.86,"value":1406335.12,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,292 shares on February 13, 2026 and becomes exercisable in annual increments of 7,292 on February 13, 2027, and 7,291 on February 13, 2028."}],"balance_after":14583,"derivative":{"exercise_price":192.86,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":7292},"source":{"system":"sec-edgar","filing":"0001951400-26-000004","document":"form4-02272026_050202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000195140026000004/form4-02272026_050202.xml","form_type":"4"}},{"id":12777,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11031,"kind":"person","name":"Siatis Perry C","position":1,"cik":"0001951400","reported_name":"Siatis Perry C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC AND SECRETARY"}}],"security":"Option (Right to buy)","published_at":"2026-02-27T22:00:05.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":false,"shares":7775,"price":175.28,"value":1362802.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,775 on February 15, 2025 and 7,775 on February 15, 2026, and becomes exercisable as to 7,774 shares on February 15, 2027."}],"balance_after":7774,"derivative":{"exercise_price":175.28,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":7775},"source":{"system":"sec-edgar","filing":"0001951400-26-000004","document":"form4-02272026_050202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000195140026000004/form4-02272026_050202.xml","form_type":"4"}},{"id":12776,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11031,"kind":"person","name":"Siatis Perry C","position":1,"cik":"0001951400","reported_name":"Siatis Perry C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC AND SECRETARY"}}],"security":"Option (Right to buy)","published_at":"2026-02-27T22:00:05.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":false,"shares":7314,"price":149.62,"value":1094320.68,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,315 on February 16, 2024, 7,315 on February 16, 2025, and 7,314 on February 16, 2026."}],"balance_after":0,"derivative":{"exercise_price":149.62,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":7314},"source":{"system":"sec-edgar","filing":"0001951400-26-000004","document":"form4-02272026_050202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000195140026000004/form4-02272026_050202.xml","form_type":"4"}},{"id":12775,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11031,"kind":"person","name":"Siatis Perry C","position":1,"cik":"0001951400","reported_name":"Siatis Perry C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC AND SECRETARY"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-27T22:00:05.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":22381,"price":230,"value":5147630.0,"ownership":{"direct":true},"balance_after":38137,"source":{"system":"sec-edgar","filing":"0001951400-26-000004","document":"form4-02272026_050202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000195140026000004/form4-02272026_050202.xml","form_type":"4"}},{"id":12774,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11031,"kind":"person","name":"Siatis Perry C","position":1,"cik":"0001951400","reported_name":"Siatis Perry C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC AND SECRETARY"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-27T22:00:05.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":true,"shares":7292,"price":192.86,"value":1406335.12,"ownership":{"direct":true},"balance_after":60518,"source":{"system":"sec-edgar","filing":"0001951400-26-000004","document":"form4-02272026_050202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000195140026000004/form4-02272026_050202.xml","form_type":"4"}},{"id":12773,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11031,"kind":"person","name":"Siatis Perry C","position":1,"cik":"0001951400","reported_name":"Siatis Perry C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC AND SECRETARY"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-27T22:00:05.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":true,"shares":7775,"price":175.28,"value":1362802.0,"ownership":{"direct":true},"balance_after":53226,"source":{"system":"sec-edgar","filing":"0001951400-26-000004","document":"form4-02272026_050202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000195140026000004/form4-02272026_050202.xml","form_type":"4"}},{"id":12772,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11031,"kind":"person","name":"Siatis Perry C","position":1,"cik":"0001951400","reported_name":"Siatis Perry C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC AND SECRETARY"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-27T22:00:05.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":true,"shares":7314,"price":149.62,"value":1094320.68,"ownership":{"direct":true},"balance_after":45451,"source":{"system":"sec-edgar","filing":"0001951400-26-000004","document":"form4-02272026_050202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000195140026000004/form4-02272026_050202.xml","form_type":"4"}},{"id":13211,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Option (Right to buy)","published_at":"2026-02-20T23:36:48.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":21937,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,313 on February 18, 2027, 7,312  on February 18, 2028, and 7,312 on February 18, 2029."}],"balance_after":21937,"derivative":{"exercise_price":230.04,"expiration_date":"2036-02-17","underlying":"Common Stock","underlying_shares":21937},"source":{"system":"sec-edgar","filing":"0002004979-26-000002","document":"form4-02202026_110244.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000200497926000002/form4-02202026_110244.xml","form_type":"4"}},{"id":13210,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:36:48.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":6638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":60413,"source":{"system":"sec-edgar","filing":"0002004979-26-000002","document":"form4-02202026_110244.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000200497926000002/form4-02202026_110244.xml","form_type":"4"}},{"id":13209,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:36:48.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":3346,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":53775,"source":{"system":"sec-edgar","filing":"0002004979-26-000002","document":"form4-02202026_110244.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000200497926000002/form4-02202026_110244.xml","form_type":"4"}},{"id":13208,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:36:48.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":2138,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":50429,"source":{"system":"sec-edgar","filing":"0002004979-26-000002","document":"form4-02202026_110244.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000200497926000002/form4-02202026_110244.xml","form_type":"4"}},{"id":13207,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:36:48.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":6015,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":48291,"source":{"system":"sec-edgar","filing":"0002004979-26-000002","document":"form4-02202026_110244.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000200497926000002/form4-02202026_110244.xml","form_type":"4"}},{"id":13231,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11034,"kind":"person","name":"Stewart Jeffrey Ryan","position":1,"cik":"0001761675","reported_name":"Stewart Jeffrey Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Option (Right to Buy)","published_at":"2026-02-20T23:35:24.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":26812,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,938 on February 18, 2027, 8,937 on February 18, 2028, and 8,937 on February 18, 2029."}],"balance_after":26812,"derivative":{"exercise_price":230.04,"expiration_date":"2036-02-17","underlying":"Common Stock","underlying_shares":26812},"source":{"system":"sec-edgar","filing":"0001761675-26-000002","document":"form4-02202026_060213.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000176167526000002/form4-02202026_060213.xml","form_type":"4"}},{"id":13230,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11034,"kind":"person","name":"Stewart Jeffrey Ryan","position":1,"cik":"0001761675","reported_name":"Stewart Jeffrey Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:24.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":8988,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":106983,"source":{"system":"sec-edgar","filing":"0001761675-26-000002","document":"form4-02202026_060213.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000176167526000002/form4-02202026_060213.xml","form_type":"4"}},{"id":13229,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11034,"kind":"person","name":"Stewart Jeffrey Ryan","position":1,"cik":"0001761675","reported_name":"Stewart Jeffrey Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:24.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":9432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":97995,"source":{"system":"sec-edgar","filing":"0001761675-26-000002","document":"form4-02202026_060213.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000176167526000002/form4-02202026_060213.xml","form_type":"4"}},{"id":13228,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11034,"kind":"person","name":"Stewart Jeffrey Ryan","position":1,"cik":"0001761675","reported_name":"Stewart Jeffrey Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:24.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":9266,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":88563,"source":{"system":"sec-edgar","filing":"0001761675-26-000002","document":"form4-02202026_060213.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000176167526000002/form4-02202026_060213.xml","form_type":"4"}},{"id":13227,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11034,"kind":"person","name":"Stewart Jeffrey Ryan","position":1,"cik":"0001761675","reported_name":"Stewart Jeffrey Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:24.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":26063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":79297,"source":{"system":"sec-edgar","filing":"0001761675-26-000002","document":"form4-02202026_060213.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000176167526000002/form4-02202026_060213.xml","form_type":"4"}},{"id":13216,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11031,"kind":"person","name":"Siatis Perry C","position":1,"cik":"0001951400","reported_name":"Siatis Perry C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC AND SECRETARY"}}],"security":"Option (Right to buy)","published_at":"2026-02-20T23:35:21.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,500 on February 18, 2027, 6,500 on February 18, 2028, and 6,500 on February 18, 2029."}],"balance_after":19500,"derivative":{"exercise_price":230.04,"expiration_date":"2036-02-17","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001951400-26-000002","document":"form4-02202026_060211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000195140026000002/form4-02202026_060211.xml","form_type":"4"}},{"id":13215,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11031,"kind":"person","name":"Siatis Perry C","position":1,"cik":"0001951400","reported_name":"Siatis Perry C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC AND SECRETARY"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:21.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":5808,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":38137,"source":{"system":"sec-edgar","filing":"0001951400-26-000002","document":"form4-02202026_060211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000195140026000002/form4-02202026_060211.xml","form_type":"4"}},{"id":13214,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11031,"kind":"person","name":"Siatis Perry C","position":1,"cik":"0001951400","reported_name":"Siatis Perry C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC AND SECRETARY"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:21.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":5628,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":32329,"source":{"system":"sec-edgar","filing":"0001951400-26-000002","document":"form4-02202026_060211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000195140026000002/form4-02202026_060211.xml","form_type":"4"}},{"id":13213,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11031,"kind":"person","name":"Siatis Perry C","position":1,"cik":"0001951400","reported_name":"Siatis Perry C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC AND SECRETARY"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:21.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":5792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":26701,"source":{"system":"sec-edgar","filing":"0001951400-26-000002","document":"form4-02202026_060211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000195140026000002/form4-02202026_060211.xml","form_type":"4"}},{"id":13212,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11031,"kind":"person","name":"Siatis Perry C","position":1,"cik":"0001951400","reported_name":"Siatis Perry C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, GC AND SECRETARY"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:21.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":16290,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":20909,"source":{"system":"sec-edgar","filing":"0001951400-26-000002","document":"form4-02202026_060211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000195140026000002/form4-02202026_060211.xml","form_type":"4"}},{"id":13270,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Option (Right to Buy)","published_at":"2026-02-20T23:35:18.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":20312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,771 on February 18, 2027, 6,771 on February 18, 2028, and 6,770 on February 18, 2029."}],"balance_after":20312,"derivative":{"exercise_price":230.04,"expiration_date":"2036-02-17","underlying":"Common Stock","underlying_shares":20312},"source":{"system":"sec-edgar","filing":"0001563545-26-000002","document":"form4-02202026_060209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000156354526000002/form4-02202026_060209.xml","form_type":"4"}},{"id":13269,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:18.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":6638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":214103,"source":{"system":"sec-edgar","filing":"0001563545-26-000002","document":"form4-02202026_060209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000156354526000002/form4-02202026_060209.xml","form_type":"4"}},{"id":13268,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:18.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":7074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":207465,"source":{"system":"sec-edgar","filing":"0001563545-26-000002","document":"form4-02202026_060209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000156354526000002/form4-02202026_060209.xml","form_type":"4"}},{"id":13267,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:18.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":6058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":200391,"source":{"system":"sec-edgar","filing":"0001563545-26-000002","document":"form4-02202026_060209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000156354526000002/form4-02202026_060209.xml","form_type":"4"}},{"id":13266,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:18.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":17041,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":194333,"source":{"system":"sec-edgar","filing":"0001563545-26-000002","document":"form4-02202026_060209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000156354526000002/form4-02202026_060209.xml","form_type":"4"}},{"id":13199,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11009,"kind":"person","name":"Crum Demetris D","position":1,"cik":"0002078592","reported_name":"Crum Demetris D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF HR OFFICER"}}],"security":"Option (Right to buy)","published_at":"2026-02-20T23:35:14.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":13406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,469 on February 18, 2027, 4,469 on February 18, 2028, and 4,468 on February 18, 2029."}],"balance_after":13406,"derivative":{"exercise_price":230.04,"expiration_date":"2036-02-17","underlying":"Common Stock","underlying_shares":13406},"source":{"system":"sec-edgar","filing":"0002078592-26-000002","document":"form4-02202026_060208.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000207859226000002/form4-02202026_060208.xml","form_type":"4"}},{"id":13198,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11009,"kind":"person","name":"Crum Demetris D","position":1,"cik":"0002078592","reported_name":"Crum Demetris D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF HR OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:14.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":1244,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":9508,"source":{"system":"sec-edgar","filing":"0002078592-26-000002","document":"form4-02202026_060208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000207859226000002/form4-02202026_060208.xml","form_type":"4"}},{"id":13197,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11009,"kind":"person","name":"Crum Demetris D","position":1,"cik":"0002078592","reported_name":"Crum Demetris D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF HR OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:14.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":1216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":8264,"source":{"system":"sec-edgar","filing":"0002078592-26-000002","document":"form4-02202026_060208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000207859226000002/form4-02202026_060208.xml","form_type":"4"}},{"id":13226,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Option (Right to buy)","published_at":"2026-02-20T23:35:13.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":20312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,771 on February 18, 2027, 6,771 on February 18, 2028, and 6,770 on February 18, 2029."}],"balance_after":20312,"derivative":{"exercise_price":230.04,"expiration_date":"2036-02-17","underlying":"Common Stock","underlying_shares":20312},"source":{"system":"sec-edgar","filing":"0001762951-26-000002","document":"form4-02202026_060205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000002/form4-02202026_060205.xml","form_type":"4"}},{"id":13225,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:13.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":6222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":87304,"source":{"system":"sec-edgar","filing":"0001762951-26-000002","document":"form4-02202026_060205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000002/form4-02202026_060205.xml","form_type":"4"}},{"id":13224,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:13.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":5172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":81082,"source":{"system":"sec-edgar","filing":"0001762951-26-000002","document":"form4-02202026_060205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000002/form4-02202026_060205.xml","form_type":"4"}},{"id":13223,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:13.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":4632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":75910,"source":{"system":"sec-edgar","filing":"0001762951-26-000002","document":"form4-02202026_060205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000002/form4-02202026_060205.xml","form_type":"4"}},{"id":13222,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:13.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":13031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":71278,"source":{"system":"sec-edgar","filing":"0001762951-26-000002","document":"form4-02202026_060205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000176295126000002/form4-02202026_060205.xml","form_type":"4"}},{"id":13221,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11032,"kind":"person","name":"Reents Scott T","position":1,"cik":"0001937048","reported_name":"Reents Scott T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF FINANCIAL OFFICER"}}],"security":"Option (Right to buy)","published_at":"2026-02-20T23:35:09.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":21937,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,313 on February 18, 2027, 7,312 on February 18, 2028, and 7,312 on February 18, 2029."}],"balance_after":21937,"derivative":{"exercise_price":230.04,"expiration_date":"2036-02-17","underlying":"Common Stock","underlying_shares":21937},"source":{"system":"sec-edgar","filing":"0001937048-26-000002","document":"form4-02202026_060204.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000193704826000002/form4-02202026_060204.xml","form_type":"4"}},{"id":13220,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11032,"kind":"person","name":"Reents Scott T","position":1,"cik":"0001937048","reported_name":"Reents Scott T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:09.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":7260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":60415,"source":{"system":"sec-edgar","filing":"0001937048-26-000002","document":"form4-02202026_060204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000193704826000002/form4-02202026_060204.xml","form_type":"4"}},{"id":13219,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11032,"kind":"person","name":"Reents Scott T","position":1,"cik":"0001937048","reported_name":"Reents Scott T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:09.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":7606,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":53155,"source":{"system":"sec-edgar","filing":"0001937048-26-000002","document":"form4-02202026_060204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000193704826000002/form4-02202026_060204.xml","form_type":"4"}},{"id":13218,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11032,"kind":"person","name":"Reents Scott T","position":1,"cik":"0001937048","reported_name":"Reents Scott T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:09.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":8910,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":45549,"source":{"system":"sec-edgar","filing":"0001937048-26-000002","document":"form4-02202026_060204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000193704826000002/form4-02202026_060204.xml","form_type":"4"}},{"id":13217,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11032,"kind":"person","name":"Reents Scott T","position":1,"cik":"0001937048","reported_name":"Reents Scott T","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:35:09.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":25062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":36639,"source":{"system":"sec-edgar","filing":"0001937048-26-000002","document":"form4-02202026_060204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000193704826000002/form4-02202026_060204.xml","form_type":"4"}},{"id":13204,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10993,"kind":"person","name":"Purdue David Ryan","position":1,"cik":"0002057696","reported_name":"Purdue David Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Controller"}}],"security":"Option (Right to buy)","published_at":"2026-02-20T18:35:27.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":4875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 1,625 on February 18, 2027, 1,625 on February 18, 2028, and 1,625 on February 18, 2029."}],"balance_after":4875,"derivative":{"exercise_price":230.04,"expiration_date":"2036-02-17","underlying":"Common Stock","underlying_shares":4875},"source":{"system":"sec-edgar","filing":"0002057696-26-000002","document":"form4-02202026_060215.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2057696/000205769626000002/form4-02202026_060215.xml","form_type":"4"}},{"id":13203,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10993,"kind":"person","name":"Purdue David Ryan","position":1,"cik":"0002057696","reported_name":"Purdue David Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T18:35:27.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":1384,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":10576,"source":{"system":"sec-edgar","filing":"0002057696-26-000002","document":"form4-02202026_060215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2057696/000205769626000002/form4-02202026_060215.xml","form_type":"4"}},{"id":13202,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10993,"kind":"person","name":"Purdue David Ryan","position":1,"cik":"0002057696","reported_name":"Purdue David Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T18:35:27.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":1292,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":9192,"source":{"system":"sec-edgar","filing":"0002057696-26-000002","document":"form4-02202026_060215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2057696/000205769626000002/form4-02202026_060215.xml","form_type":"4"}},{"id":13201,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10993,"kind":"person","name":"Purdue David Ryan","position":1,"cik":"0002057696","reported_name":"Purdue David Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T18:35:27.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":7900,"source":{"system":"sec-edgar","filing":"0002057696-26-000002","document":"form4-02202026_060215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2057696/000205769626000002/form4-02202026_060215.xml","form_type":"4"}},{"id":13200,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10993,"kind":"person","name":"Purdue David Ryan","position":1,"cik":"0002057696","reported_name":"Purdue David Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Controller"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T18:35:27.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":2505,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":7010,"source":{"system":"sec-edgar","filing":"0002057696-26-000002","document":"form4-02202026_060215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2057696/000205769626000002/form4-02202026_060215.xml","form_type":"4"}},{"id":13236,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Option (Right to Buy)","published_at":"2026-02-20T18:35:06.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":81251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,084 on February 18, 2027, 27,084 on February 18, 2028, and 27,083 on February 18, 2029."}],"balance_after":81251,"derivative":{"exercise_price":230.04,"expiration_date":"2036-02-17","underlying":"Common Stock","underlying_shares":81251},"source":{"system":"sec-edgar","filing":"0001699914-26-000002","document":"form4-02202026_060201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000169991426000002/form4-02202026_060201.xml","form_type":"4"}},{"id":13235,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T18:35:06.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":22124,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":215260,"source":{"system":"sec-edgar","filing":"0001699914-26-000002","document":"form4-02202026_060201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000169991426000002/form4-02202026_060201.xml","form_type":"4"}},{"id":13234,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T18:35:06.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":14452,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":193136,"source":{"system":"sec-edgar","filing":"0001699914-26-000002","document":"form4-02202026_060201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000169991426000002/form4-02202026_060201.xml","form_type":"4"}},{"id":13233,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T18:35:06.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":12030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":178684,"source":{"system":"sec-edgar","filing":"0001699914-26-000002","document":"form4-02202026_060201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000169991426000002/form4-02202026_060201.xml","form_type":"4"}},{"id":13232,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11036,"kind":"person","name":"Michael Robert A.","position":1,"cik":"0001699914","reported_name":"Michael Robert A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T18:35:06.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":33833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":166654,"source":{"system":"sec-edgar","filing":"0001699914-26-000002","document":"form4-02202026_060201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699914/000169991426000002/form4-02202026_060201.xml","form_type":"4"}},{"id":15629,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10966,"kind":"person","name":"Alpern Robert J","position":1,"cik":"0001448074","reported_name":"Alpern Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Equivalent Units","published_at":"2026-01-05T22:00:18.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":34,"price":228.49,"value":7768.66,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature."}],"balance_after":10257,"derivative":{"exercise_price":228.49,"underlying":"Common Stock","underlying_shares":34},"source":{"system":"sec-edgar","filing":"0001448074-26-000003","document":"form4-01052026_050110.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448074/000144807426000003/form4-01052026_050110.xml","form_type":"4"}},{"id":15616,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10585,"kind":"person","name":"Quaggin Susan E","position":1,"cik":"0001997505","reported_name":"Quaggin Susan E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Equivalent Units","published_at":"2026-01-05T22:00:15.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":68,"price":228.49,"value":15537.32,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature."}],"balance_after":707,"derivative":{"exercise_price":228.49,"underlying":"Common Stock","underlying_shares":68},"source":{"system":"sec-edgar","filing":"0001997505-26-000002","document":"form4-01052026_050108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1997505/000199750526000002/form4-01052026_050108.xml","form_type":"4"}},{"id":15635,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10596,"kind":"person","name":"RAPP EDWARD J","position":1,"cik":"0001171780","reported_name":"RAPP EDWARD J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Equivalent Units","published_at":"2026-01-05T22:00:10.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":147,"price":228.49,"value":33588.03,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature."}],"balance_after":28498,"derivative":{"exercise_price":228.49,"underlying":"Common Stock","underlying_shares":147},"source":{"system":"sec-edgar","filing":"0001171780-26-000002","document":"form4-01052026_050107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1171780/000117178026000002/form4-01052026_050107.xml","form_type":"4"}},{"id":18842,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10585,"kind":"person","name":"Quaggin Susan E","position":1,"cik":"0001997505","reported_name":"Quaggin Susan E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Equivalent Units","published_at":"2025-10-02T21:00:41.000Z","date":"2025-09-30","kind":"grant","planned":false,"acquired":true,"shares":67,"price":231.54,"value":15513.18,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature."}],"balance_after":634,"derivative":{"exercise_price":231.54,"underlying":"Common Stock","underlying_shares":67},"source":{"system":"sec-edgar","filing":"0001997505-25-000005","document":"form4-10022025_051001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1997505/000199750525000005/form4-10022025_051001.xml","form_type":"4"}},{"id":18854,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10966,"kind":"person","name":"Alpern Robert J","position":1,"cik":"0001448074","reported_name":"Alpern Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Equivalent Units","published_at":"2025-10-02T21:00:17.000Z","date":"2025-09-30","kind":"grant","planned":false,"acquired":true,"shares":33,"price":231.54,"value":7640.82,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature."}],"balance_after":10151,"derivative":{"exercise_price":231.54,"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001448074-25-000012","document":"form4-10022025_051004.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448074/000144807425000012/form4-10022025_051004.xml","form_type":"4"}},{"id":18891,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10596,"kind":"person","name":"RAPP EDWARD J","position":1,"cik":"0001171780","reported_name":"RAPP EDWARD J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Equivalent Units","published_at":"2025-10-02T21:00:12.000Z","date":"2025-09-30","kind":"grant","planned":false,"acquired":true,"shares":145,"price":231.54,"value":33573.3,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature."}],"balance_after":28152,"derivative":{"exercise_price":231.54,"underlying":"Common Stock","underlying_shares":145},"source":{"system":"sec-edgar","filing":"0001171780-25-000004","document":"form4-10022025_051003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1171780/000117178025000004/form4-10022025_051003.xml","form_type":"4"}},{"id":20800,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Option (Right to Buy)","published_at":"2025-08-14T21:00:06.000Z","date":"2025-08-12","kind":"exercise","planned":false,"acquired":false,"shares":42370,"price":54.86,"value":2324418.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 14,124 on February 18, 2017, 14,123 on February 18, 2018, and 14,123 on February 18, 2019."}],"balance_after":0,"derivative":{"exercise_price":54.86,"expiration_date":"2026-02-17","underlying":"Common Stock","underlying_shares":42370},"source":{"system":"sec-edgar","filing":"0001415889-25-021944","document":"form4-08142025_050801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925021944/form4-08142025_050801.xml","form_type":"4"}},{"id":20799,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-08-14T21:00:06.000Z","date":"2025-08-12","kind":"sale","planned":false,"acquired":false,"shares":42370,"price":198.42,"value":8407055.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.34 to $198.58, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":177292,"source":{"system":"sec-edgar","filing":"0001415889-25-021944","document":"form4-08142025_050801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925021944/form4-08142025_050801.xml","form_type":"4"}},{"id":20798,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11038,"kind":"person","name":"SALEKI-GERHARDT AZITA","position":1,"cik":"0001563545","reported_name":"SALEKI-GERHARDT AZITA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF OPERATIONS OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-08-14T21:00:06.000Z","date":"2025-08-12","kind":"exercise","planned":false,"acquired":true,"shares":42370,"price":54.86,"value":2324418.2,"ownership":{"direct":true},"balance_after":219662,"source":{"system":"sec-edgar","filing":"0001415889-25-021944","document":"form4-08142025_050801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925021944/form4-08142025_050801.xml","form_type":"4"}},{"id":21052,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-08-07T21:00:06.000Z","date":"2025-08-05","kind":"sale","planned":false,"acquired":false,"shares":10061,"price":198.59,"value":1998013.99,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.56 to $198.73 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":58247,"source":{"system":"sec-edgar","filing":"0001415889-25-021280","document":"form4-08072025_050802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588925021280/form4-08072025_050802.xml","form_type":"4"}},{"id":21051,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10427,"kind":"person","name":"Donoghoe Nicholas","position":1,"cik":"0001762951","reported_name":"Donoghoe Nicholas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CHIEF BUS/STRAT OFFICER"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-08-07T21:00:06.000Z","date":"2025-08-05","kind":"sale","planned":false,"acquired":false,"shares":3234.17,"price":198.27,"value":641238.8859,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.26 to $198.37 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This reflects shares acquired pursuant to a dividend reinvestment plan."}],"balance_after":68308,"source":{"system":"sec-edgar","filing":"0001415889-25-021280","document":"form4-08072025_050802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1762951/000141588925021280/form4-08072025_050802.xml","form_type":"4"}},{"id":22043,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10966,"kind":"person","name":"Alpern Robert J","position":1,"cik":"0001448074","reported_name":"Alpern Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Equivalent Units","published_at":"2025-07-02T21:00:13.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":40,"price":185.62,"value":7424.8,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature."}],"balance_after":10038,"derivative":{"exercise_price":185.62,"underlying":"Common Stock","underlying_shares":40},"source":{"system":"sec-edgar","filing":"0001415889-25-019106","document":"form4-07022025_050704.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448074/000141588925019106/form4-07022025_050704.xml","form_type":"4"}},{"id":22042,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10596,"kind":"person","name":"RAPP EDWARD J","position":1,"cik":"0001171780","reported_name":"RAPP EDWARD J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Equivalent Units","published_at":"2025-07-02T21:00:10.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":177,"price":185.62,"value":32854.74,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature."}],"balance_after":27785,"derivative":{"exercise_price":185.62,"underlying":"Common Stock","underlying_shares":177},"source":{"system":"sec-edgar","filing":"0001415889-25-019107","document":"form4-07022025_050706.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1171780/000141588925019107/form4-07022025_050706.xml","form_type":"4"}},{"id":22044,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10585,"kind":"person","name":"Quaggin Susan E","position":1,"cik":"0001997505","reported_name":"Quaggin Susan E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Equivalent Units","published_at":"2025-07-02T21:00:09.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":81,"price":185.62,"value":15035.22,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature."}],"balance_after":562,"derivative":{"exercise_price":185.62,"underlying":"Common Stock","underlying_shares":81},"source":{"system":"sec-edgar","filing":"0001415889-25-019105","document":"form4-07022025_050701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1997505/000141588925019105/form4-07022025_050701.xml","form_type":"4"}},{"id":24066,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":10826,"kind":"person","name":"FALK THOMAS J","position":1,"cik":"0001222890","reported_name":"FALK THOMAS J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.01 par value","published_at":"2025-05-13T21:05:30.000Z","date":"2025-05-09","kind":"grant","planned":false,"acquired":true,"shares":1203,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the \"Program\"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from\nservice, death, or the occurrence of a change in control (as defined in the Program)."}],"balance_after":1203,"source":{"system":"sec-edgar","filing":"0001415889-25-012804","document":"form4-05132025_050526.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1222890/000141588925012804/form4-05132025_050526.xml","form_type":"4"}}],"next_cursor":"2025-05-13T21:05:30.000000Z,24066"}